EGFR and neoplasm: Several studies have shown that inhibiting EGFR using anti-EGFR inhibitors modulates the tumor immune microenvironment, with the effects including the enhancement of MHC class I and II expression, a decrease in the suppressive function of Tregs, the promotion of CTL activity, and reduced T cell apoptosis [77–80].